Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600442 | 1.00 | KMT2A (0.41) | KMT2ACYP1A2MEN1MAPK1HIF1A | |
| SCHEMBL30887629 | 0.96 | HTR2A (0.40) | KMT2ACYP1A2MEN1MAPK1HIF1A | |
| SCHEMBL5962787 | 0.91 | ERBB2 (0.36) | KMT2ACYP1A2MEN1MAPK1HIF1A | |
| SCHEMBL19339957 | 0.90 | HTR2C (0.40) | KMT2ACYP1A2MEN1MAPK1HIF1A | |
| SCHEMBL20468018 | 0.82 | ERBB2 (0.38) | KMT2AERBB2HRASMAPT | |
| SCHEMBL18232120 | 0.82 | ERBB2 (0.38) | KMT2AERBB2HRASMAPT | |
| SCHEMBL4408064 | 0.82 | ERBB2 (0.50) | KMT2AMEN1MAPK1HSD17B10HTR2A | |
| SCHEMBL12364479 | 0.82 | ERBB2 (0.50) | KMT2AMEN1MAPK1HSD17B10HTR2A | |
| SCHEMBL1149405 | 0.79 | ERBB2 (0.46) | KMT2AMEN1HTR2AHTR2CHTR2B | |
| SCHEMBL14421001 | 0.79 | ERBB2 (0.46) | KMT2AMEN1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124573-A | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-107074879-B | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | KMT2A 2390/4885CYP1A2 260/4885MEN1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.